Zydus Cadila, an innovation-driven global pharmaceutical company today announced that the Drug Controller General of India (DCGI) has approved its New Drug Application (NDA) for Saroglitazar Mg for the treatment of Non-alcoholic Fatty Liver Disease (NAFLD) in India. The prevalence of
NAFLD in India is estimated to be nearly 25-30% of the general population. This approval for NAFLD alongwith either of the comorbidities (Obesity, Type 2 Diabetes Mellitus, Dyslipidemia or Metabolic Syndrome) provides the physicians with a viable treatment option.
With a once daily, 4mg dose regimen, Saroglitazar Mg will enable better compliance, reduces the pill burden and offers the patient more convenience.
Zydus announces the approval of Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease in India
Posted On: 2020-12-29 21:54:07 (Time Zone: Arizona, USA)
Zydus Cadila, an innovation-driven global pharmaceutical company today announced that the Drug Controller General of India (DCGI) has approved its New Drug Application (NDA) for Saroglitazar Mg for the treatment of Non-alcoholic Fatty Liver Disease (NAFLD) in India. The prevalence of NAFLD in India is estimated to be nearly 25-30% of the general population. This approval for NAFLD alongwith either of the comorbidities (Obesity, Type 2 Diabetes Mellitus, Dyslipidemia or Metabolic Syndrome) provides the physicians with a viable treatment option. With a once daily, 4mg dose regimen, Saroglitazar Mg will enable better compliance, reduces the pill burden and offers the patient more convenience.
ENDRA Life Sciences and GE Healthcare extend collaboration
Rating saved
ENDRA Life Sciences, the developer of Thermo Acoustic Enhanced Ultrasound (TAEUS), has renewed its collaboration agreement with GE Healthcare, extending the agreement s previous 12-month term by an additional two years.
TAEUS visualizes tissue in a way that is comparable to MR, according to ENDRA, but at a small fraction of the cost and at the point of care. The technology is designed to work in concert with the over one million ultrasound systems in use globally today.
Through the collaboration, GE will continue to support ENDRA s efforts to commercialize a fatty liver diagnostic application by facilitating introductions to its clinical ultrasound customers worldwide. In return, ENDRA will afford GE certain rights of first offer with respect to manufacturing and licensing the application.
(2)
ANN ARBOR, MI / ACCESSWIRE / December 23, 2020 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS
®), has recently been issued Chinese Patent ZL 2018 8 00500526 (the 526 patent) entitled Method and System for Estimating Fractional Fat Content of an Object from the Chinese Intellectual Property Office (SIPO).
This is the eighth Chinese patent issued to ENDRA for its TAEUS technology. ENDRA s intellectual property (IP) portfolio currently stands at 78 assets, including those in preparation, filed, issued and licensed. The 526 patent strengthens IP protection for our proprietary approach to assessing fat content in tissue. Our TAEUS system provides a non-invasive assessment of liver fat, which is particularly important in China where an estimated 30% of its 1.4 billion citizens are affected by Non-Alcoholic Fatty Liver Disease (NAFLD), said Francois Michelon, ENDRA s chief executive officer.
ENDRA Life Sciences Issued Chinese Patent for Its TAEUS(R) Platform Technology to Calculate Fat Concentration in Tissue albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.